Few British life-science names have reinvented themselves as decisively as the company once known as Oxford Biomedica. For most of its listed life it was best understood as a science house with a promising gene-therapy platform and an uneven commercial record. Today, trading as OXB, it presents itself as a pure-play contract development and manufacturing organisation for cell and gene therapies — selling capacity and know-how rather than owning medicines.
The Quick Version
- OXB rebranded from Oxford Biomedica in September 2024 to signal its shift to a pure-play cell and gene therapy CDMO; the LSE ticker remains OXB.
- FY2025 revenue reached £168.7m, up 31% reported, with a modest positive operating EBITDA and net cash of £55.4m at year end.
- The group operates sites in Oxford (UK), Lyon and Strasbourg (France, via the 2024 ABL Europe acquisition) and Bedford and Durham (US).
- In February 2026 OXB signed a multi-year commercial lentiviral-vector supply agreement with Bristol Myers Squibb for CAR-T programmes.
- Management guided to FY2026 revenue of £220m-£240m; as a services business, execution, client concentration and utilisation are central risks.
What OXB Actually Does
OXB is a specialist manufacturer of viral vectors — engineered biological carriers that deliver genetic material into cells and underpin many cell and gene therapies. It develops manufacturing processes for biotech and pharmaceutical clients and produces material across clinical and commercial stages, spanning lentiviral vectors (widely used in CAR-T cell therapies), AAV, adenovirus and other formats. It doesn't own the therapies it makes; revenue derives from development fees, manufacturing runs, procurement and historical licences/royalties.
The Bristol Myers Squibb Deal, Explained
Announced 4 February 2026, this multi-year commercial supply agreement covers manufacturing and supplying lentiviral vectors for BMS's CAR-T cell therapy programmes, with an initial five-year term and extension options, drawing on OXB's Oxford and Durham sites. It builds on a relationship first established in 2020 and marks a transition from clinical to commercial manufacturing. Commercial supply is expected to commence during 2026, subject to relevant regulatory approvals — an important caveat, since the value hinges on the underlying therapies reaching and remaining on the market.
The Sites Behind the Story
The purchase of ABL Europe from Institut Mérieux, completed early 2024, added French AAV and adenovirus sites at Lyon and Strasbourg. In the US, the group built an AAV presence around a Boston-area operation (Bedford), later moving to full ownership, and added an FDA-approved facility in Durham, North Carolina for around $4.5m. Together these underpin the 'pure-play, global CDMO' positioning.
The Numbers
For the year ended 31 December 2025, revenue was £168.7m, up 31% on £128.8m in 2024 (33% at constant currency to £170.9m). Growth was led by manufacturing services (£81.1m) and development services (£60.1m), with procurement services rising sharply to £22.3m. Gross profit rose to £66.0m. Operating EBITDA was a modest £2.3m as reported (£8.1m constant currency), attributed partly to non-recurring Durham-related items. Cash and equivalents were £96.9m, net cash £55.4m, up from £20.6m a year earlier. A verified revenue backlog of roughly £204m provides forward visibility.
Management guided to FY2026 revenue of £220m-£240m and an operating EBITDA margin around 10%, with medium-term ambitions of 25-30% revenue growth in FY2027-28 and EBITDA margins toward 20%-plus.
Competitive Position
OXB competes in a crowded field of contract manufacturers, differentiating on more than two decades of viral-vector experience, proprietary process technologies (including its TetraVecta lentiviral system and dual-plasmid AAV technology) and a footprint spanning UK, continental Europe and the US. The BMS agreement lends external validation to its manufacturing credentials. Client concentration is a structural feature of the model — a handful of large programmes can drive a disproportionate share of revenue.
Risks Worth Weighing
Demand is cyclical and can be lumpy, leaving expensive facilities underutilised if client programmes slip. Client concentration means the loss or delay of a major programme could have an outsized effect. Because OXB doesn't own the underlying therapies, it's exposed to third-party clinical and regulatory outcomes it can't influence — the BMS commercial supply is explicitly subject to regulatory approval of the relevant products. Execution and integration risk is elevated by recent expansion, bringing acquired sites to full, compliant utilisation.
What to Watch Next
The commencement of commercial lentiviral supply to BMS during 2026, subject to approvals. Additional multi-year supply agreements, particularly ones converting clinical clients into commercial customers. Evidence of improving utilisation across French and US sites. Progress toward the guided FY2026 revenue range and margin trajectory.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...